RECEIVED
CENTRAL FAX CENTER
AUG 21 2006

Amendment to the Claims:

1. (currently amended) A piperazinyl pyrimidinyl nitroso compound of the formula (II)



II

where (P)-R_N is:

-N=O,

(P)-R_{N-1}-O-OC-$(CH_2)_{n1}$- where n_1 is 1 ~~thru~~ through 6 and ~~where~~ (P)-R_{N-1} is H- or C_1-C_4 alkyl,

or C_1-C_6 alkyl[[,]] ;

where (P)-R_{2-1} is:

-N=O ~~and~~ or

C_1-C_6 alkyl;

where (P)-R_{2-2} is:

C_1-C_6 alkyl; ~~and~~ or

where (P)-R_{2-1} and (P)-R_{2-2} are taken together with the attached nitrogen atom to form a ring selected from the group consisting of: pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and 4-nitroso-1-piperazinyl;

where (P)-R_{4-1} is

-N=O and or

C_1-C_6 alkyl; ~~and~~

where (P)-R_{4-2} is

C_1-C_6 alkyl; ~~and~~ or

where (P)-R_{4-1} and (P)-R_{4-2} are taken together with the attached nitrogen atom to form a ring selected from the group consisting of: pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and 4-nitroso-1-piperazinyl;

~~and~~ or a pharmaceutically acceptable ~~salts~~ salt thereof.

2. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where the variable substituents (P)-R_{2-1} and (P)-R_{2-2} are the same as the variable substituents (P)-R_{4-1} and (P)-R_{4-2}.

3. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where (P)-R_{2-1} and (P)-R_{2-2}, and (P)-R_{4-1} and (P)-R_{4-2} are both taken together with the attached nitrogen atom to form pyrrolidinyl.

4. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 which contains 3 –N=O groups.

5. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 which contains 4 –N=O groups.

6. (currently amended) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids: acetic, aspartic, benzenesulfonic, benzoic, bicarbonic, bisulfuric, biartaric, butyric, calcium edetate, camsylic, carbonic, chlorobenzoic, citric, edetic, edisylic, estolic, esyl, esylic, formic, fumaric, gluceptic, gluconic, glutamic, glycollylarsanilic, hexamic, hexylresorcinoic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, maleic, malic, malonic, mandelic, methanesulfonic, methylnitric, methylsuffuric, mucic, muconoic, napsylic, nitric, oxalic, p-nitromethanesulfonic, pamoic, pantothenic, phosphoric,

monohydrogen phosphoric, dihydrogen phosphoric, phthalic, polygalacturonic, propionic, salicyclic, stearic, succinic, ~~succinic,~~ sulfamic, sulfanilic, sulfonic, tannic, tartaric, teoclic, and toluenesulfonic.

7. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where (P)-R_N is –N=O.

8. (currently amended) A piperazinyl pyrimidinyl nitroso compound according to claim 7 where the ~~substituted pyrimidinyl nitroso~~ compound is 5-nitroso-2,4-di(1-pyrrolidinyl)-6-(4-nitroso-1-piperazinyl)pyrimidine.

9. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where (P)-R_N is (P)-R_{N-1}-O-OC-$(CH_2)_{n1}$-.

10. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 9 where the piperazinyl pyrimidinyl nitroso compound is 5-nitroso-2,4-di(1-pyrrolidinyl)-6-[4-(3-propionic acid methyl ester)piperazin-1-yl]pyrimidine.

11. (canceled)

12. (canceled)

13. (currently amended) A method of treating ischemic injury in a human ~~who has an ischemic disease selected from the group consisting of coronary heart disease, stroke, hemorrhagic shock, peripheral vascular disease (upper and lower extremities) and transplant related injuries and who is in need of treatment which comprises~~ in need thereof comprising administering to ~~that~~ the human an ~~anti-ischemic~~ effective amount of a piperazinyl pyrimidinyl nitroso compound of formula (II)



II

where (P)-R_N is:

-N=O,

(P)-R_{N-1}-O-OC-$(CH_2)_{n1}$- where n_1 is 1 ~~thru~~ through 6 and ~~where~~ (P)-R_{N-1} is H- or C_1-C_4 alkyl,

or C_1-C_6 alkyl[[,]] ;

where (P)-R_{2-1} is:

-N=O ~~and~~ or

C_1-C_6 alkyl;

where (P)-R_{2-2} is:

C_1-C_6 alkyl; ~~and~~ or

where (P)-R_{2-1} and (P)-R_{2-2} are taken together with the attached nitrogen atom to form a ring selected from the group consisting of: pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and 4-nitroso-1-piperazinyl;

where (P)-R_{4-1} is

-N=O ~~and~~ or

C_1-C_6 alkyl; ~~and~~

where (P)-R_{4-2} is

C_1-C_6 alkyl; ~~and~~ or

where (P)-R_{2-1} and (P)-R_{2-2} are taken together with the attached nitrogen atom to form a ring selected from the group consisting of: pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and 4-nitroso-1-piperazinyl;



(IV)

~~and~~ or a pharmaceutically acceptable salt thereof.

14. (currently amended) A method of ~~treating a human who has an ischemic disease according to~~ claim 13 where the ~~administering is IV or oral~~ compound is administered intravenously or orally.

15. (currently amended) A method of ~~treating a human who has an ischemic disease according to~~ claim 13 where the ~~IV anti-ischemic~~ compound is administered intravenously and the effective amount is from about 5 to about 100 mg/kg/dose.

16. (currently amended) A method of ~~treating a human who has an ischemic disease according to~~ claim 13 where the ~~oral anti-ischemic~~ compound is administered orally and the effective amount is from about 5 to about 50 mg/kg/dose.

17. (canceled)

18. (currently amended) A method of ~~treating a human who has an ischemic disease according to~~ claim 17 where the piperazinyl pyrimidinyl nitroso compound (II) is 5-nitroso-2,4-di(1-pyrrolidinyl)-6-(4-nitroso-1-piperazinyl)pyrimidine or 5-

nitroso-2,4-di(1-pyrrolidinyl)-6-[4-(3-propionic acid methyl ester)piperazin-1-yl]pyrimidine.